IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Russell A. HOUSER, et al.

Group Art Unit: 3734

Serial Number: 10/785,486

Examiner: Michele Lindsey Bachman

Filing Date: February 24, 2004

CONFIRMATION NO: 1784

Title: PATCHES AND COLLARS FOR MEDICAL APPLICATIONS AND

METHODS OF USE

FILED ELECTRONICALLY ON: February

9,2009

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Sir:

An Information Disclosure Statement along with attached PTO/SB/08 is hereby submitted. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

The Examiner is requested to review the information provided and to make the information of record in the above-identified application. The Examiner is further requested to initial and return the attached PTO/SB/08 in accordance with MPEP §609.

The right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered, is hereby reserved.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

A.	≥ 37 CF. because:	R §1.97	(b). This Information Disclosure Statement should be considered by the Office
		(1)	It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under §1.53(d);
			OR
		(2)	It is being filed within 3 months of entry of the national stage as set forth in §1.491 in an international application;
			OR
		(3)	It is being filed before the mailing of a first Office action on the merits;
			OR
	\boxtimes	(4)	It is being filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
В.	specified in office action	c). Although this Information Disclosure Statement is being filed after the period $(R, \S1.97(b))$, above, it is filed before the mailing date of the earlier of (1) a final $(\S1.113, \S1.113)$, (2) a notice of allowance under $\S1.311$, or (3) an action that otherwise on the merits, this Information Disclosure Statement should be considered because by one of:	
		a stater	ment as specified in §1.97(e) provided concurrently herewith;
			OR
			f \$180.00 as set forth in \$1.17(p) authorized below, enclosed, or included with the nt of other papers filed together with this statement.
C.	date of the	earlier o	d). Although this Information Disclosure Statement is being filed after the mailing of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311, fore payment of the issue fee and should be considered because it is accompanied
		i. a st	atement as specified in §1.97(e);
			AND
			ee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included he the payment of other papers filed together with this Statement.
D.	☐ 37 CFI	R §1.97(e). Statement.
		A state	ment is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);
			AND/OR
		A state	ment is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);
			AND/OR
		inform the cor	of a dated communication from a foreign patent office clearly showing that the ation disclosure statement is being submitted within 3 months of the filing date on munication is provided in lieu of a statement under 37 C.F.R. § 1.97(e)(1) as ed for under MPEP 609.04(b) V.
E.	disclosure application	statemer that wa	der 37 C.F.R. §1.704(d). Each item of information contained in the information at was first cited in a communication from a foreign patent office in a counterpart is received by an individual designated in § 1.56(c) not more than thirty (30) days of this information disclosure statement. This statement is made pursuant to the

	for Applicant(s) delay.					
F.	☑ 37 CFR §1.98(a)(2). The content of the Information Disclosure Statement is as follows:					
		Copies herewit	of each of the references listed on the attached Form PTO/SB/08 are enclosed th.			
			OR			
	\boxtimes	Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are NOT enclosed.				
			AND/OR			
			of Foreign Patent Documents and/or Non Patent Literature Documents listed on ached Form PTO/SB/08 are enclosed in accordance with 37 CFR §1.98 (a)(2).			
			AND/OR			
		of pending unpublished U.S. patent applications are enclosed in accordance with \$1.98(a)(2)(iii).				
G.	\square 37 CFR §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/o references.					
			nt to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, ation or other information provided that is not in English is provided herewith.			
			Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.			
	į		OR			
			A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows:			
			nt to 37 CFR §1.98(a)(3)(ii), a copy of a translation, or a portion thereof, of the aglish language reference(s) is provided herewith.			
H.	37 CFR §1.98(d). Copies of patents, publications and pending U.S. patent applications, or oth information specified in 37 C.F.R. § 1.98(a) are not provided herewith because:					
		Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement, or cited by examiners, for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.				
		Applic	ation in which the information was submitted:			
		Information Disclosure Statement(s) filed on:				
			AND			
			formation disclosure statement submitted in the earlier application complied with aphs (a) through (c) of 37 CFR §1.98.			

requirements of 37 C.F.R. §1.704(d) to avoid reduction of the period of adjustment of the patent term

I.

Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No. 37163-709.305).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: February

, 2009

Cecily Anne O'Regan, Reg. No. 37,448

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 021971